Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
about
A review of malaria vaccine clinical projects based on the WHO rainbow tableSelf-assembling protein nanoparticles in the design of vaccinesAntibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.Subviral particle as vaccine and vaccine platform.Regulation of CD8+ T cell responses to infection with parasitic protozoa.HIV p24 as scaffold for presenting conformational HIV Env antigens.Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis.Seroprevalence of malaria in inhabitants of the urban zone of Antananarivo, Madagascar.Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humansBig-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals.Malaria vaccines in development.Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity.Virus-like particles: flexible platforms for vaccine development.Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms.Use of hepadnavirus core proteins as vaccine platforms.Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Virus-like particles in vaccine development.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions.Hepatitis B core-based virus-like particles to present heterologous epitopes.Advances and challenges in the development and production of effective plant-based influenza vaccines.Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trialAn IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis.Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis.Escherichia coli-derived virus-like particles in vaccine development.
P2860
Q21034112-F93777A9-76FD-4D54-991E-91026CE8BA01Q26767097-CE9B6C96-221F-45AE-ADBC-5296031483F4Q30384943-93C5C874-EE17-421E-8B96-8EE2345E7F5DQ33318466-73DA8025-BEE6-439A-8AD8-78F0B1D5E1FBQ33812653-3A6C6AFD-4B87-4E60-886A-26ED40E894B8Q34108177-5C320459-54B5-43D7-B50F-4AE619C68ED5Q34389522-681185DE-0EA2-4BF6-9605-D5DB77B46B93Q34573891-CA6CDF1D-451D-4C19-AA3E-83A79EA3EEA2Q35073970-AECB4CC8-C92C-485F-986A-A96DD3CDBC83Q35136750-DEED9A1F-DDD5-4D6C-B23C-276C12B76654Q35157517-446B5E6B-6FDE-4634-B06C-4E3263656C4EQ35586865-D31FC227-CD33-4D6E-B47B-8D299CAD65EBQ35789759-54692329-BAAB-456C-B3BB-3ACBA0835BC3Q36219634-8EFA9C98-A930-44F5-BCCC-31B31B922BDFQ36228375-82CDC93B-8A9E-400C-A567-57FFF586181DQ36383811-93450334-73FB-415E-93AD-689A1A819AEEQ36728808-CA426054-CE2E-461E-9570-B5C1AA476326Q36837144-3F548C75-3DDE-450E-A20E-F7A33AA1D1CFQ37036065-7262127B-D40D-4BD1-A499-5DC50FC5E554Q37039140-60C88DB2-CAFD-4979-A1E7-CFC36DCFE67BQ37547757-6AE8B669-8701-4C4B-A646-588F00ACA110Q37622906-25B0AAF4-55AD-48AF-976B-4936CEAA49CFQ37792984-E193D3A8-8E47-49B6-9395-1D6B356B0909Q37798008-FFB4BCB7-20A4-4ED6-B9CC-87F1EEB39F35Q37812128-C1F28A22-AFE8-4306-83DB-BBE29E709203Q37951525-1A155528-1FCD-4063-AE2E-A4B67F3AC687Q38059751-2259AD0E-6EEB-46FA-8F84-4D5FDB407F6DQ38081969-8D85AADA-5F8B-4206-8BFB-337A23429C06Q38285425-2058FBD5-2C39-46FF-A5EE-EFDE03EB5B5AQ42754531-593069FD-949A-455C-A6D4-1CDD2467F160Q42827899-FFB10E97-48F3-4963-8979-E83FBDA58317Q43238854-9E86E5DA-C57F-4F2C-8161-8677309FA81EQ46699505-C45E57FE-2E74-4132-BF85-AC2FCE2ABEFBQ47132009-58D0B20D-836D-4BE7-A43B-E8EEE67873BE
P2860
Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase I testing of a malaria v ...... rum circumsporozoite epitopes.
@en
type
label
Phase I testing of a malaria v ...... rum circumsporozoite epitopes.
@en
prefLabel
Phase I testing of a malaria v ...... rum circumsporozoite epitopes.
@en
P2093
P2860
P1476
Phase I testing of a malaria v ...... arum circumsporozoite epitopes
@en
P2093
Annette Schmidt
Ashley J Birkett
Carolin Maier
Elizabeth H Nardin
Giane A Oliveira
J Mauricio Calvo-Calle
Kristiane Wetzel
Michael L Corado
Pramod Sarpotdar
P2860
P304
P356
10.1128/IAI.72.11.6519-6527.2004
P407
P577
2004-11-01T00:00:00Z